Ramadan N M
Lilly Research Laboratories, Eli Lilly & Co. and Indiana University School of Medicine, Indianapolis, Indiana 46285, USA.
Curr Med Res Opin. 2001;17 Suppl 1:s81-6. doi: 10.1185/0300799039117018.
In Chapter 14, blind alleys in acute anti-migraine drug development were discussed. In this chapter, future therapies are covered. There is growing interest and support for the use of CGRP antagonists, nitric oxide synthase inhibitors, and ionotropic glutamate receptor antagonists. The hope is to strike the balance of high efficacy with minimal to no safety concern and good tolerability. Some of the targets discussed in this chapter have been in early efficacy trials and others are in first human dose stages. Large-scale efficacy and safety trials are eagerly awaited.
在第14章中，讨论了急性抗偏头痛药物研发中的死胡同。在本章中，将介绍未来的治疗方法。人们对使用降钙素基因相关肽（CGRP）拮抗剂、一氧化氮合酶抑制剂和离子型谷氨酸受体拮抗剂的兴趣和支持日益增加。希望能在高疗效与最低至无安全问题及良好耐受性之间取得平衡。本章讨论的一些靶点已进入早期疗效试验阶段，其他靶点则处于首次人体给药阶段。人们急切期待大规模的疗效和安全性试验。
